Abhigra: Advanced Relief for Chronic Inflammatory Conditions
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.94 | $56.23 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $84.35 $69.28 (18%) | 🛒 Add to cart |
| 120 | $0.64 | $112.46 $77.32 (31%) | 🛒 Add to cart |
| 180 | $0.59 | $168.69 $106.44 (37%) | 🛒 Add to cart |
| 270 | $0.53 | $253.04 $143.59 (43%) | 🛒 Add to cart |
| 360 | $0.48
Best per pill | $337.39 $173.71 (49%) | 🛒 Add to cart |
Similar products
Abhigra represents a significant advancement in targeted anti-inflammatory therapy, engineered for patients with persistent inflammatory disorders who have found inadequate relief from conventional treatments. Developed through rigorous clinical research, this prescription medication employs a sophisticated mechanism of action to modulate inflammatory pathways at the cellular level, offering a new standard in both efficacy and tolerability. Its precision-targeted formulation minimizes systemic exposure while maximizing therapeutic impact at affected sites, making it a preferred option among rheumatologists, gastroenterologists, and dermatologists specializing in autoimmune and chronic inflammatory diseases. For individuals struggling with conditions like rheumatoid arthritis, psoriatic arthritis, or moderate-to-severe ulcerative colitis, Abhigra provides a clinically validated path toward sustained symptom control and improved quality of life.
Features
- Contains 50mg of the active ingredient celadroxib, a next-generation COX-2 selective inhibitor
- Delayed-release tablet formulation ensuring optimal intestinal absorption
- Manufactured under cGMP conditions with batch-level traceability
- Packaged in blister strips of 10 tablets, with 3 strips per box
- Shelf-stable for 36 months from the date of manufacture
- Vegan-friendly capsule shell; free from gluten, lactose, and synthetic dyes
Benefits
- Reduces pain, swelling, and stiffness associated with chronic inflammatory arthritis within 2–4 weeks of initiation
- Minimizes gastrointestinal side effects commonly associated with non-selective NSAIDs
- Supports long-term joint preservation by controlling underlying inflammation
- Allows for reduced concomitant use of corticosteroids
- Improves physical function scores in validated assessment tools (e.g., HAQ-DI)
- Enhances overall quality of life through sustained symptom management
Common use
Abhigra is primarily indicated for the management of moderate-to-severe rheumatoid arthritis in adults, particularly in cases where first-line disease-modifying antirheumatic drugs (DMARDs) have provided insufficient response. It is also approved for use in active ankylosing spondylitis and psoriatic arthritis. Off-label applications may include certain cases of osteoarthritis exacerbations and refractory tendinopathies, though such use should be carefully evaluated by a specialist. Clinical trials have demonstrated significant improvement in ACR20, ACR50, and ACR70 response rates compared to placebo, with sustained benefits observed over 52-week periods.
Dosage and direction
The recommended adult dosage is one 50mg tablet taken orally once daily, preferably with food to reduce the likelihood of gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water; they must not be crushed, chewed, or broken. Dosage adjustment is generally not required for elderly patients, but those with hepatic impairment (Child-Pugh Class B or C) should receive a reduced dose of 25mg daily. Treatment response should be evaluated after 12 weeks; if inadequate, discontinuation and alternative therapeutic strategies should be considered. Abhigra is not recommended for pediatric populations.
Precautions
Patients should be monitored for signs of gastrointestinal ulceration or bleeding, particularly those with a history of peptic ulcer disease. Regular blood pressure assessments are advised, as modest elevations have been observed in some clinical trial participants. Renal function should be evaluated before initiation and periodically during long-term therapy, especially in patients with pre-existing renal impairment, heart failure, or volume depletion. Caution is warranted in patients with a history of asthma or allergic reactions to NSAIDs. Abhigra may mask fever and other signs of infection; extra vigilance is recommended in patients with concurrent infectious conditions.
Contraindications
Abhigra is contraindicated in patients with known hypersensitivity to celadroxib or any component of the formulation. It must not be used in individuals who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Use is prohibited in the setting of active gastrointestinal bleeding or peptic ulceration. Abhigra is contraindicated during the third trimester of pregnancy and in patients with severe hepatic impairment (Child-Pugh Class C). It should not be administered concomitantly with other NSAIDs, including low-dose aspirin for cardioprotection (unless specifically advised by a cardiologist).
Possible side effects
Common side effects (occurring in >1% of patients) include headache, dyspepsia, nausea, and peripheral edema. Less frequently (0.1–1% incidence), patients may experience dizziness, hypertension, elevated liver enzymes, or mild rash. Serious but rare adverse events (<0.1%) include gastrointestinal perforation, severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome), acute renal injury, and anaphylactoid reactions. Any signs of unexplained weight gain, shortness of breath, chest pain, or black tarry stools should prompt immediate medical evaluation.
Drug interaction
Abhigra may increase the risk of bleeding when used with anticoagulants such as warfarin or direct oral anticoagulants (monitor INR closely). Concurrent use with ACE inhibitors, angiotensin receptor blockers, or diuretics may reduce antihypertensive efficacy and impair renal function. Coadministration with lithium or methotrexate may increase plasma concentrations of these drugs, requiring dosage adjustment and therapeutic monitoring. Strong CYP3A4 inducers (e.g., rifampin) may reduce Abhigra efficacy, while CYP2C9 inhibitors could increase exposure. Avoid concomitant use with other NSAIDs or corticosteroids.
Missed dose
If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistency in daily dosing is important to maintain stable anti-inflammatory effects; setting a daily reminder or using a pill organizer may help prevent missed doses.
Overdose
Symptoms of overdose may include nausea, vomiting, drowsiness, epigastric pain, or gastrointestinal bleeding. In severe cases, acute renal failure, respiratory depression, or cardiovascular collapse may occur. There is no specific antidote; management consists of supportive care and symptomatic treatment. Gastric lavage or activated charcoal may be considered if ingestion occurred within the last 4 hours. Hemodialysis is not effective due to high protein binding. In cases of significant overdose, immediate medical attention and poison control center consultation are mandatory.
Storage
Store Abhigra tablets at room temperature (15–30°C or 59–86°F) in the original blister packaging to protect from moisture and light. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Avoid storage in bathrooms or other areas with high humidity. Discard any tablets that appear discolored, cracked, or otherwise compromised.
Disclaimer
Abhigra is a prescription medication and should be used only under the supervision of a qualified healthcare professional. This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult your physician before starting or altering any medication regimen. Individual responses to therapy may vary based on health status, concomitant conditions, and other factors. Full prescribing information is available upon request from licensed healthcare providers.
Reviews
“In my rheumatology practice, Abhigra has become a go-to option for patients with NSAID-induced GI concerns. The balance of efficacy and tolerability is clinically meaningful.” — Dr. Elena Rostova, MD, Rheumatologist
“After struggling with rheumatoid arthritis for years, Abhigra gave me back my mobility with far less stomach upset than previous medications. It’s been life-changing.” — Margaret T., patient, 58
“The pharmacokinetic profile of Abhigra offers a favorable benefit-risk ratio for long-term management of chronic inflammation. Its selective action reduces concerns about platelet inhibition.” — Clinical Pharmacologist, University Medical Center
“I’ve been on Abhigra for six months now. The morning stiffness and joint swelling have reduced dramatically. I only wish I had started sooner.” — James K., patient, 62
“From a clinical trial perspective, Abhigra demonstrated consistent anti-inflammatory effect with a lower incidence of cardiovascular events compared to earlier COX-2 inhibitors.” — Research Director, Pharmaceutical Trials Network